Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor
cells and slow the growth of the tumor.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have
locally advanced or metastatic breast cancer.